News|Articles|November 17, 2026

Gilead Signs Royalty-Free Licensing Deals to Broaden Access to Obeldesivir

Listen
0:00 / 0:00

Key Takeaways

  • Royalty-free licenses authorize contingent manufacturing and distribution of obeldesivir within 127 countries, aligned with prior remdesivir COVID-19 licensing geographies and intended to compress timelines post-approval.
  • Technology transfer planning has begun with three named manufacturers, and additional partners are being pursued to expand capacity before confirmatory clinical and regulatory milestones.
SHOW MORE

Gilead signs royalty-free licensing agreements with three generic manufacturers to expand future access to its investigational antiviral obeldesivir.

Gilead Sciences signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis for Ebola Bundibugyo virus disease.

The agreements will cover 127 primarily low- and lower-middle-income countries, including all African countries that have reported cases during the current Ebola BVD outbreak.1 The move signals Gilead’s effort to get ahead of a currently ongoing outbreak by lining up manufacturing and supply capacity before clinical results are even in.

The geographic scope of the new agreements mirrors Gilead’s existing voluntary licensing arrangements for remdesivir in Covid-19, with the agreements being designed to support manufacturing readiness, technology transfer, and supply planning, while a field trial evaluating obeldesivir continues.1

What do the agreements cover?

The royalty-free licenses allow Dr. Reddy’s Laboratories, Eva Pharma, and Ferozsons Laboratories to manufacture and supply obeldesivir in the licensed territory, contingent on clinical data and applicable regulatory authorizations.1 Technology transfer discussions are already underway with these three manufacturers, with Gilead saying agreements with additional manufacturers are under discussion.

What trial is evaluating obeldesivir?

Obeldesivir is currently being evaluated in the Ebo-pep trial, a partner-led Phase III randomized, placebo-controlled field trial coordinated by ALIMA and partners.2 The trial is evaluating the efficacy of obeldesivir as post-exposure prophylaxis for individuals at high risk of developing Ebola BVD.2 Obeldesivir has previously been evaluated in clinical trials for Covid-19 and respiratory syncytial virus, in addition to its preclinical filovirus activity.

The drug is currently not approved for post-exposure prophylaxis of filovirus disease, or for any indication, in any country.1

Jaime McCoy, vice president, Gilead Patient Solutions, Gilead Sciences, says responding to emerging infectious diseases, including Ebola virus disease, requires not only scientific innovation, but also early planning and collaboration to help ensure that effective medicines can reach the people who need them as quickly as possible. He continues to say, “These agreements reflect our commitment to preparing for future access while clinical research is ongoing, so that we are better positioned to respond if these investigational medicines demonstrate benefit and gain regulatory approval.”

How has Gilead already responded to the outbreak?

Beyond the new licensing agreements, Gilead has made direct product donations tied to the current outbreak. The company has donated more than 2,000 vials of remdesivir to Kenya for investigational use as treatment and post-exposure prophylaxis for people with confirmed Ebola BVD or individuals with a close contact exposure.1 More broadly, as part of its response to the current outbreak, Gilead has provided compassionate use donations of remdesivir to the Democratic Republic of the Congo, Uganda, and Kenya totaling more than 38,000 vials.

These efforts sit within what Gilead describes as a broader approach to outbreak preparedness that includes clinical research, manufacturing and supply planning, technology transfer, and collaboration with governments, public health agencies and global health partners.

The licensing announcement is one piece of a broader outbreak response. Gilead is also updating its existing voluntary licensing agreements for remdesivir to include filovirus disease, which would support potential future access should results from the ongoing World Health Organization-sponsored Partners trial support remdesivir’s use as a treatment for Ebola BVD, pending potential regulatory approvals.1 The clinical efficacy of remdesivir for the treatment of Ebola BVD has not been established, and remdesivir is not currently approved in any country for the treatment or prevention of the disease.

Sources

  1. Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing Gilead Sciences November 16, 2026, https://www.gilead.com/news/news-details/2026/gilead-expands-access-to-investigational-obeldesivir-for-ebola-bundibugyo-virus-disease-through-voluntary-licensing
  2. Filovirus Post-Exposure Prophylaxis, preparedness and efficacy evaluation during outbreak in Central and West-Africa Global Health EDCTP3 August 1, 2026, https://www.global-health-edctp3.europa.eu/projects/ebo-pep-2026_en

Related to this article